Hims Drops Compounded Semaglutide: What the Novo Nordisk Deal Means for You
Hims partnered with Novo Nordisk, stopped advertising compounded GLP-1s, and now offers FDA-approved Wegovy starting at $149/month. Here's what changes for patients.
Hims & Hers ended its compounded semaglutide program in spring 2026 and announced a partnership with Novo Nordisk to distribute brand-name Wegovy direct to patients. For Hims customers and patients evaluating telehealth options, the change matters.
Key takeaways
- Hims now sells brand-name Wegovy at a negotiated cash price
- Compounded semaglutide patients on Hims need to migrate or switch providers
- The deal does not change anything for compounded patients on other platforms
- Total cost on Hims is higher than typical compounded plans but lower than retail pharmacy
What the deal includes
Hims is now an authorized distributor for Wegovy at a manufacturer-supported cash price, plus its standard provider consult and shipping infrastructure. Novo Nordisk gains a high-volume direct-to-consumer channel; Hims gains access to FDA-approved supply without compounding regulatory exposure.
Hims customers on compounded semaglutide have been offered migration paths to either Wegovy or, in some cases, refunded plan balances.
How it affects the broader market
It signals that the largest telehealth players are starting to bifurcate — some will keep compounding under more regulated conditions, others will pivot to brand-name distribution at higher price points. The compounded segment is consolidating around providers with stronger pharmacy partnerships.
For patients, the practical impact is more provider differentiation. The cheapest options are increasingly compounded-only specialists rather than the largest brand-name telehealth platforms.